CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Calls for Patient Input: Benlysta, Onstryv and Takhzyro

Published on: April 30, 2019
Result type: News

CADTH has received the following notice(s) of pending drug submission(s).

Benlysta

Brand name Benlysta
Generic name belimumab
Manufacturer GlaxoSmithKline Inc.
Indication(s) Systemic lupus erythematosus
Project Number SR0616-000
Call for patient input 2019-04-30
Patient input deadline 2019-06-19
Submit patient input Submit
Register as Clinical Expert Register

Onstryv

Brand name Onstryv
Generic name safinamide
Manufacturer Valeo Pharma Inc.
Indication(s) Parkinson's disease
Project Number SR0617-000
Call for patient input 2019-04-30
Patient input deadline 2019-06-19
Submit patient input Submit
Register as Clinical Expert Register

Takhzyro

Brand name Takhzyro
Generic name lanadelumab
Manufacturer Takeda Canada Inc.
Indication(s) Hereditary angioedema, prevention
Project Number SR0618-000
Call for patient input 2019-04-30
Patient input deadline 2019-06-19
Submit patient input Submit
Register as Clinical Expert Register